83 patents
Page 4 of 5
Utility
Co-stimulatory Domains for Use In Genetically-modified Cells
23 Dec 20
The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition.
Derek Jantz, Aaron Martin, Daniel T. MacLeod
Filed: 8 Sep 20
Utility
Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
30 Nov 20
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV).
Derek Jantz, James Jefferson Smith
Filed: 16 Apr 20
Utility
Genetically-modified Immune Cells Comprising a Microrna-adapted Shrna (Shrnamir)
25 Nov 20
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
Filed: 21 Jun 20
Utility
Nucleic Acid Molecules Encoding an Engineered Antigen Receptor and an Inhibitory Nucleic Acid Molecule and Methods of Use Thereof
28 Oct 20
The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule.
Joann Hux, Aaron Martin, Derek Jantz, Clayton Beard
Filed: 12 Jul 20
Utility
Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
12 Oct 20
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene.
Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
Filed: 4 Oct 16
Utility
Co-stimulatory domains for use in genetically-modified cells
12 Oct 20
The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition.
Derek Jantz, Aaron Martin, Daniel T. MacLeod
Filed: 10 Oct 19
Utility
Self-limiting Viral Vectors Encoding Nucleases
30 Sep 20
Disclosed herein are viral vectors for use in recombinant molecular biology techniques.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 13 Apr 20
Utility
Engineered Nucleases That Target Human and Canine Factor VIII Genes As a Treatment for Hemophilia a
23 Sep 20
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the int22h-1 sequence of a Factor VIII gene.
Armin Hekele, Clayton Beard, Derek Jantz, James Jefferson Smith, Victor Bartsevich
Filed: 31 Oct 18
Utility
Treatment of retinitis pigmentosa using engineered meganucleases
31 Aug 20
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele.
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 13 Feb 20
Utility
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
17 Aug 20
The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule.
Joann Hux, Aaron Martin, Derek Jantz, Clayton Beard
Filed: 7 Nov 19
Utility
Modified Epidermal Growth Factor Receptor Peptides for Use In Genetically-modified Cells
29 Jul 20
The present disclosure provides modified EGFR peptides useful in genetically-modified cells to allow for selection and enrichment of those cells expressing the modified EGFR peptide.
Derek Jantz, James Jefferson Smith, Daniel T. MacLeod
Filed: 2 Oct 18
Utility
Engineered Meganucleases Specific for Recognition Sequences In the Hepatitis B Virus Genome
29 Jul 20
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV).
Derek Jantz, James Jefferson Smith
Filed: 16 Apr 20
Utility
Methods for Reducing Dna-induced Cytotoxicity and Enhancing Gene Editing In Primary Cells
17 Jun 20
An obstacle in the use of many primary cells is the significant cytotoxicity observed following transfection with circular or linearized DNA.
Mark Johnson
Filed: 29 Apr 18
Utility
Treatment of Retinitis Pigmentosa Using Engineered Meganucleases
10 Jun 20
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele.
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 13 Feb 20
Utility
Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
25 May 20
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV).
Derek Jantz, James Jefferson Smith
Filed: 12 Oct 17
Utility
Self-limiting viral vectors encoding nucleases
25 May 20
Disclosed herein are viral vectors for use in recombinant molecular biology techniques.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 19 Jun 16
Utility
Engineered Meganucleases Specific for Recognition Sequences In the PCSK9 Gene
29 Apr 20
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within the human PCSK9 gene.
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Janel Lape
Filed: 19 Apr 18
Utility
Genetically-modified T Cells Comprising a Modified Intron In the T Cell Receptor Alpha Gene
22 Apr 20
The present invention provides a genetically-modified T cell comprising in its genome a modified human T cell receptor alpha gene.
Derek Jantz, James Jefferson Smith, Clayton Beard
Filed: 26 Jun 18
Utility
Treatment of retinitis pigmentosa using engineered meganucleases
30 Mar 20
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele.
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 7 Sep 16
Utility
Nucleic Acid Molecules Encoding an Engineered Antigen Receptor and an Inhibitory Nucleic Acid Molecule and Methods of Use Thereof
26 Feb 20
The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule.
Joann Hux, Aaron Martin, Derek Jantz, Clayton Beard
Filed: 7 Nov 19